New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease
Authors:
- David C. UnderwoodDUDavid C. Underwood
- 1 March 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 6 (2) , 164-169
Abstract
Phosphodiesterase 4 (PDE4) is member of the growing family of proteins that regulate the intracellular concentrations of cyclic AMP and cyclic GMP. Earliest described inhibitors of PDE4, such as rolipram, demonstrate marked anti-inflammatory and bronchodilatory effects in vitro and in vivo. The clinical utility of these earlier compounds was limited by their propensity to elicit gastrointestinal side effects. This has led to an extensive effort to identify novel PDE4 inhibitors that maintain the anti-inflammatory activity and bronchodilatory activity of rolipram but with a reduced potential to produce side effects. This article summarizes the evidence supporting the utility of selective PDE4 inhibitors in the treatment of asthma and chronic obstructive pulmonary disease, discusses the recent results obtained in clinical trials with second-generation inhibitors, and presents two approaches designed to identify additional novel selective PDE4 inhibitors.Keywords
This publication has 38 references indexed in Scilit:
- Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart diseaseThe Journal of Thoracic and Cardiovascular Surgery, 1998
- PDE4 inhibition and a corticosteroid in chronically antigen exposed conscious guinea‐pigsClinical & Experimental Allergy, 1998
- Effect of PDE4 inhibitors on zymosan‐induced IL‐8 release from human neutrophils: synergism with prostanoids and salbutamolBritish Journal of Pharmacology, 1998
- 1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of AsthmaJournal of Medicinal Chemistry, 1998
- Human Recombinant Phosphodiesterase 4B2B Binds (R)-Rolipram at a Single Site with Two AffinitiesBiochemistry, 1997
- Effects of inhibitors of phosphodiesterase, on antigen‐induced bronchial hyperreactivity in conscious sensitized guinea‐pigs and airway leukocyte infiltrationBritish Journal of Pharmacology, 1997
- Effects of selective and non-selective phosphodiesterase inhibitors on tracheal mucus secretion in the ratEuropean Journal of Pharmacology, 1996
- Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: Relationship to elevated cAMP levelsBiochemical Pharmacology, 1995
- Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigsEuropean Journal of Pharmacology, 1995
- The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin‐induced airway changes in ratsClinical & Experimental Allergy, 1993